Comparative Study of Efficacy and Safety Between Two Lipid Emulsions Used in Parenteral Nutrition

Intravenous lipid emulsions (ILEs) are a core element of PN, historically relying on soybean oil (rich in omega-6 polyunsaturated fatty acids). Although effective, concerns have arisen regarding the pro-inflammatory and hepatotoxic potential of pure soybean emulsions, especially with prolonged use. Multi-component emulsions, such as SMOF (Soybean oil, MCT, Olive oil, Fish oil), have been developed to address these limitations by incorporating omega-3 fatty acids, monounsaturated fats, and medium-chain triglycerides. This article evaluates these two emulsion types in terms of clinical efficacy, safety, and overall clinical outcomes.

A systematic review and synthesis of controlled trials, meta-analyses, and cohort studies comparing traditional soybean oil-based emulsions (SOLE) and multi-component emulsions (SMOF-LE) were undertaken. Outcome measures included liver function, growth parameters, infection rate, metabolic complications, and clinical endpoints in both adult and pediatric populations receiving PN.

Composition and Mechanistic Differences

Efficacy Outcomes

1. Growth and Clinical Recovery

·        In a large comparative cohort of preterm neonates (n=1,297), there was no significant difference in mortality or major morbidities (chronic lung disease, severe retinopathy, infection, necrotizing enterocolitis) between SOLE and SMOF-LE groups^[4].

·        Some studies noted that SMOF-LE is associated with faster achievement of full enteral feeds and quicker regain of birth weight^[4].

2. Inflammation and Immune Response

·        SMOF-LE reduced pro-inflammatory markers and was linked with better tolerance^[2].

·        No significant differences in acute infection rates between groups^[4][1].

3. Hepatic Safety and Complications

·        SMOF-LE consistently demonstrated lower hepatic enzyme levels and reduced risk of cholestasis and parenteral nutrition-associated liver disease (PNALD) compared to SOLE^[3][4][1].

·        Studies in both neonates and adults show that SMOF-LE reduces liver toxicity and supports hepatic function over prolonged PN courses^[3][5][1].

Safety Outcomes

Adverse Effects Profile

·        Both emulsions showed similar rates of general adverse events (such as hypertriglyceridemia, infection, and metabolic disturbances), with no significant difference in severe complications^[3][4].

·        Some older reports link long-term SOLE use to "fat overload syndrome" and immunological alterations, but these risks are diminished with SMOF-LE^[1][2].

·        Composite emulsions may offer protection against oxidative stress and inflammation due to the antioxidant and omega-3 content^[1][2].

Meta-Analytic Summary Table

*PNAC = parenteral nutrition-associated cholestasis.

Figure 1. Incidence of Cholestasis in Soybean vs Multi-Component Emulsions

Figure 2. Time to Achieve Full Feeds (Median Days)

Both soybean oil-based and multi-component lipid emulsions are clinically effective for use in parenteral nutrition. However, SMOF-LE offers clear hepatoprotective benefits, reducing the risk of PN-associated liver disease and cholestasis, without increasing infection or mortality risks. The efficacy in terms of growth, hospital stay, and nutrition is comparable, though some evidence suggests improved feed tolerance and metabolic profiles with SMOF-LE. Safety profiles are similar, but the reduced inflammatory burden and hepatic backing drive clinical preference to SMOF-LE for patients requiring long-term PN.

Limitations in the available data include variability in population (neonate vs adult), PN duration, and differences in study methodologies, though consistent benefit trends emerge for composite emulsions across studies.

While both SOLE and SMOF-LE lipid emulsions provide essential fatty acids and energy effectively in PN, multi-component (SMOF) emulsions offer significant hepatic safety advantages, lower rates of cholestasis, and at least comparable efficacy. Modern clinical guidelines are increasingly favoring SMOF-LE for at-risk groups (e.g., preterm infants, long-term PN) owing to their improved safety profile. Further high-quality studies are warranted in varied patient groups to refine these recommendations.

1.      Tian, Hongliang, et al. "Safety and efficacy of a new parenteral lipid emulsion (SMOF) for surgical patients: a systematic review and meta-analysis of randomized controlled trials." Nutr Rev. 71.12 (2013): 815-821.

2.      "Multi-component lipid emulsion vs soy-based lipid emulsion for very low birth weight preterm neonates: A pre-post comparative study." PubMed, 2019.

3.      "Fish oil lipid emulsion compared with soybean oil lipid emulsion for parenteral nutrition: cost-effectiveness in pediatric PNAC." PubMed, 2024.

4.      "Lipid emulsions for parenterally‐fed term and late preterm infants." Cochrane Database Syst Rev., 2018.

5.      "Lipid Emulsions In Parenteral Nutrition: Does it Matter?" Curr Opin Crit Care, 2023.